Candriam Equities L Biotechnology Class I GBP Cap

Register to Unlock Ratings
Performance History31/03/2024
Growth of 1,000 (GBP) Advanced Graph
Candriam Equities L Biotechnology Class I GBP Cap
Fund17.3-1.69.71.53.7
+/-Cat-8.77.417.52.81.4
+/-B’mrk-15.6-1.97.2-5.8-4.8
 
Key Stats
NAV
11/04/2024
 GBP 3377.57
Day Change 1.04%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN LU1269737059
Fund Size (Mil)
11/04/2024
 USD 1537.73
Share Class Size (Mil)
11/04/2024
 GBP 0.74
Max Initial Charge -
Ongoing Charge
17/02/2023
  0.80%
Morningstar Research
Analyst Report18/03/2024
Jeffrey Schumacher, Director
Morningstar, Inc

An expanding and highly qualified team led by one of the industry’s most seasoned investors in the field, combined with a proven process give this fund an edge. The fund’s cheapest share classes receive a Morningstar Analyst Rating of Silver,...

Click here to read this analyst report on the underlying fund.
Morningstar Pillars
People24
Parent23
Process24
Performance
Price
Investment Objective: Candriam Equities L Biotechnology Class I GBP Cap
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund as set out below and defined in the section entitled Risk factors in the Prospectus.
Returns
Trailing Returns (GBP)11/04/2024
YTD1.70
3 Years Annualised6.06
5 Years Annualised8.20
10 Years Annualised*16.29
12 Month Yield 0.00
Management
Manager Name
Start Date
Rudi Van den Eynde
06/04/2000
Linden Thomson
29/02/2024
Inception Date
08/03/2016
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Candriam Equities L Biotechnology Class I GBP Cap29/02/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock95.180.0095.18
Bond0.000.000.00
Property0.000.000.00
Cash4.820.004.82
Other0.000.000.00
Top 5 Regions%
United States84.28
United Kingdom5.07
Eurozone3.98
Europe - ex Euro3.29
Canada1.60
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Vertex Pharmaceuticals IncHealthcareHealthcare6.89
Regeneron Pharmaceuticals IncHealthcareHealthcare6.42
Amgen IncHealthcareHealthcare5.95
Gilead Sciences IncHealthcareHealthcare5.74
AstraZeneca PLCHealthcareHealthcare3.64
Candriam Equities L Biotechnology Class I GBP Cap

Related

* This share class has performance data calculated prior to the inception date, 2016-03-08. This is based upon a simulated/extended track record, using the track record of Candriam Eqs L Biotech I USD Cap (ISIN: LU0133360163), and is in accordance with Morningstar’s Extended Performance Methodology paper. To find out more about this, click here.
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures